A Supervisory Board with committed & recognized senior executives
Luc Aguilar - Scientific Senior Advisor
Luc AGUILAR gathers 20 years of experience in the biotech, pharmaceutical and the cosmetic Industry. He joined L’Oreal seven years ago to build the biotechnology Department in Advance Research. He is now leading Advanced Research activities from Scientific Knowledge to Clinical Performance for skin and hair categories. From 2005 to 2011, he was at Pierre Fabre’s Group, a mid-size pharmaceutical company, as Vice-President Scientific Affairs. During this period, he set up and led an innovation structure dedicated to clinical proof of concept studies. Prior to that, he managed operations in Biotech and start-up companies in genomics for corporate clients from 1995 to 2001. He earned a MS in Biotechnology from I.N.S.A.Toulouse, France and a PhD experience at Pierre et Marie Curie University.
Isabelle De Baillenx - Founder of FADiese
Isabelle de Baillenx created FADiese in 2001, then FADiese 2 in 2007 and FADiese 3 in 2014.
She was a pioneer of this innovative model of funding, which consists in bringing together a team of venture-capital experts and seasoned entrepreneurs eager to share their knowledge and experience with the coming generations of entrepreneurs.
She graduated from HEC business school and has acquired a significant experience in venture-capital, teaching, acquisition/divestiture consulting, judicial expertise and Secretary General in SMBs.
Isabelle also created the AFIC Entrepreneurs’ fund club
Grégoire Cayatte - Partner and Co-Founder of TechLife Capital
Grégoire Cayatte is a Managing Partner and Co-Founder of TechLife Capital. He has 18 years of operational and technological experience with Devoteam, a tech services listed company where he was CFO and a member of the Executive Committee. He led more than 50 acquisitions in 20 countries and actively contributed to the creation of 7 platforms, notably in the cybersecurity, migration to the cloud, and digital transformation. Aside from Flash Therapeutics, he is currently a Supervisory Board member of XPath Groupe (cancer diagnosis services), MyData-Trust (GDPR services for clinical trials), Maxxing (loyalty management Saas) and Hopening (fundraising for non-profit organizations) in France. Grégoire started his career in Investment Banking at Lazard and BNP Paribas. He is a graduate from Ecole Polytechnique, Ecole des Ponts ParisTech and from Institut d’Etudes Politiques.
Claudia Daugan - Investment director at Galia Gestion
Graduate of ESC Reims (RMS) and holder of DESCF, Claudia DAUGAN began her career in 1997 at KPMG Audit in Paris where she carries out statutory auditing and consulting assignments for a banking clientele. In 2000, she joined Calyon's Equity Capital Market team, which is responsible for structuring and executing the issuance of securities of major groups (listed equities and convertible bonds). From 2004 to 2009, after joining the Bordeaux region, she continued her career at Crédit Lyonnais as Deputy of Corporate Finance. She accompanies SME managers and buyers of companies in their "equity financing". Since 2009, Claudia DAUGAN has strengthened the team of investors of GALIA Gestion as Senior Business Manager and then Director of Investments. She currently follows a portfolio of a dozen companies in diversified business sectors (ICT, Services, Medical).
Franck Lescure – General partner Bioseeds IV Auriga Partners
Franck Lescure is in charge of Life Sciences investments at AURIGA Partners. He manages the Fund AURIGA IV Bioseeds specialized in Infectiology and Microbiology and is directly involved in commitments of AURIGA Partners Funds in Amoéba (Euronext: AMEBA), Cytoo, EnobraQ, Erytech Pharma (Euronext: ERYP), Fab’entech, Flashcell, Pherecydes, Median Technologies (Alternext: ALMDT), Nosopharm and Pylote. Before Auriga Partners, Franck has been part as a scientist of the five initial years of Genset, one of the first French biotech startups, he has spent several years in the Air Liquide group and has been in charge of several investments as member of the Venture Capital team of Crédit Lyonnais Private Equity which became Omnes Capital. Franck is an alumnus of the EcoleNormaleSupérieure and the Institut Pasteur. He holds a PhD in Microbiology and Virology and a MBA from the Collège des Ingénieurs
Jacques Rossignol- Partner and Co-Founder of TechLife Capital
Jacques Rossignol is a Managing Partner and Co-Founder of TechLife Capital. He has been a private equity growth investor for 18 years, has covered the healthcare industry for 17 years and the technology industry for 23 years. Aside from Flash Therapeutics, he is currently the President of the Supervisory Board of XPath Groupe (cancer diagnosis services), and used to be a Member of the Supervisory Board of Synerlab (a pharmaceutical CDMO). Before TechLife Capital, he was head of France at Alpha Private Equity, Managing Partner at 21 Invest and Director at Ekkio. He started his career in Investment Banking at BNP Paribas and Goldman Sachs (Paris, London). He is a graduate from Ecole Polytechnique and holds an MBA degree from the Harvard Business School.
A Strategic Advisory Board with accomplished senior experts
A Board of accomplished senior experts in pharmaceutical R&D, Health & Life Sciences, Gene Therapy and Branding to give strategic, innovative & accurate advices for the development of the company, especially for business development, licensing strategy, global brand strategy, regulatory affairs and therapeutic & (pre) clinical developments. Members of this Flash Therapeutics Strategic Advisory Board have a strong background in pharmacology and gene therapy, including product development, and clinical trials approval.
After 6years in Rhône Poulenc Santé, as researcher in internal medicine, then at Rhône Poulenc Agro, as toxicologist, Thierry Bardon, DVM, was head of R&D and member of the executive comitee from 1992 to 2011at Ceva Animal Health. Then, he joined Fa Diese, as director of investments in Life Sciences until now.
Olivier Danos is Executive Vice President and Chief Scientific Officer at REGENXBIO. His pioneering research work has led to the development of gene transfer technologies for gene therapy. He has played leadership roles in the Cell and Gene Therapy biopharma space over the past thirty years, including at Biogen, Genethon and at major research institutions (University College of London, Paris Necker Hospital, Centre National de la Recherche Scientifique and Institut Pasteur).
Marianne Delville is a MD/PhD specialized in Clinical Immunology, Nephrology, Gene- and Cell-therapy. She received her scientific education at the Ecole Normale Supérieure Ulm in the fields of Cell Biology and Genetics and further specialised in Immunology and Gene therapy during her PhD. After a MD thesis in Nephrology, she developed her expertise in Renal Transplantation and Cell based-therapy in Necker hospital. She is now an associate professor in Clinical Immunology in University de Paris and she recently joined One Biosciences to steer clinical project development in the field of single cells analysis.
Nicolas Ferry Ph.D - Regulatory affairs
Graduated from Paris University where he received a Ph D in 1985 and a M.D. in 1990, Nicolas served as a scientist at the French National Institute for Health Science (INSERM) for more than 25 years. He focused his interest in liver research (creation of its own INSERM lab in Nantes in 2009) and contributed to clinical trials of cell based therapy for liver diseases. Following a role of gene therapy expert for the French regulatory authority, he joined the agency as head of the department of vaccines, blood derived products and advanced therapies. Nicolas is now senior advisor at the cell therapy department of Saint Louis Hospital in Paris and works as a private consultant in the field of ATMPs. Nicolas Ferry co-authored more than 100 scientific publications.
Jean-Christophe Huertas - Global Brand Strategy & Marketing Communication
Jean-Christophe Huertas has more than 25 years of experience in Brand & Communications within worldwide companies in global and complex organizations. After 8 years (1991-1999) in media relations at Airbus, Alcatel and Rhône Poulenc (Rhodia), he was given global corporate & public affairs communications responsibilities: Rhodia Senior VP Communications & Executive Committee member (1999-2005) ; Executive VP Communications & Public Affairs of Nestlé France & Executive Committee member; Managing Director, Brand & Communications & Executive Committee member of Newedge (50/50 JV between Société Générale and Crédit Agricole), a leading Company in the world of multi-asset brokerage (2008-2012). Then, he joined in 2013 the international FTI Consulting Strategic Communications practice, as Vice-President leading the corporate communications and media Department. Since 2014, he is the CEO of H2D Advisory, a consulting & advisory firm specialized in Strategy & Communications. JC Huertas obtained a degree in law and is a graduate of the Institut d’Etudes Politiques. He as a post-graduate diploma (DESS) in Defense & International Relations of the University Paris 2 Panthéon-Assas.
Isabel Marey-Semper is a graduate of l’Ecole Normale Supérieure de la rue d’Ulm, holds a Ph.D. in Neuro-Pharmacology from Université Pierre et Marie Curie, Paris and a MBA from Collège des Ingénieurs, Paris.
Isabel started his career as a consultant in strategy and finance. Then, She served for 15 years in executive positions at established large industrial listed companies such as Compagnie de Saint Gobain S.A. and Stellantis and L’Oréal. Isabel brings her comprehensive experience in strategy, research and innovation, finance, communication and public affairs, as well as in scaling up projects.
Isabel Marey-Semper is currently a director of Aptar, a US based company as well as director of the Imagine Institute for medical research and treatment of genetic diseases, the Inria Foundation dedicated to digital science and technology and Damae Medical, a medical company focused on diagnosing skin tumors without the need for a biopsy.
Based on the founder Pascale Bouillé’s fundamental skills in HIV virology and vectorology, the company’s scientific expertise has continuously increased within the 14 years of development of Vectalys. This core competence was gradually expanded thanks to Vectalys current multidisciplinary team and its skills in genetics, cellular biology and production processes. They are today dedicated to the development and the success of Flash Therapeutics.
Pascale Bouillé Ph.D - CEO of Flash Therapeutics
Initially involved in fundamental research in retrovirology, Pascale Bouillé has worked in a number of government and biotechnology research laboratories before creating Vectalys in 2005. From her early days as a PhD student for the Gustave Roussy Institute (Professor Claude Paoletti) and postdoctoral researcher for the Pasteur Institute (Professor Luc Montagnier), she built up over 15 years' experience in R&D projects in the fields of drug discovery and virology. Pascale Bouillé then participated in various programs, first, by conducting gene therapy trials for the Genethon laboratories with Dr Olivier Danos, then followed by the successful transition of viral vector tools from a technology-based to a commercially oriented product with Vectalys. Pascale was also the CEO of FlashCell. At the head of all the Flash Therapeutics’ team as the CEO of the Company, she provides a strong scientific background and a high level of expertise to scientists, project leaders and all the clients of Flash Therapeutics worldwide.
Brigitte Mignotte-Darmon - Finance, CAO & HR
With more than 20 years' experience in the development of HR policies for international groups, Brigitte joined Vectalys in 2008. She has gained extensive knowledge from working in different R&D environments including a large American technology company and a leading CRO. Brigitte manages the administrative organization at Flash Therapeutics directing and overseeing policy related to staff and ancillary services. She ensures the development and progress of the company’s organization and has set up a genuine HR policy to support company growth and to prepare Flash Therapeutics for the developments of tomorrow.
Sophie Rimbaud - COO Partnerships and clinical programs management
With a training in biology, in management at HEC business school, and marketing & strategy in pharmaceutical environment at ESCP Paris business school. Sophie has joined Flash Therapeutics after over 25 years of experience in the pharmaceutical industry .She gained strong skills at BMS and Astra Zeneca sales department, and at LFB Group Sales & Marketing department, specialized in biological medicinal products in rare disease. Then at LFB/Cellforcure she created the Innovative Therapy department and coordinated cell and gene therapy projects from development to clinical trial, including regulatory environment, pricing and market access.
Clément Ducros - Production Manager
and industrial development
After obtaining his engineering degree in mechanical engineering (specialization in biomechanics/biomaterials) at the University of Technology of Compiègne (UTC), Clément joined the pharmaceutical industry at SANOFI in the industrial department where he piloted the installation of syringe filling lines in sterile environments. After this experience, he joined the company CARMAT which designs and develops a human artificial heart where he stayed for 13 years. First as a process development manager, he worked mainly on all aspects related to clean room manufacturing, contamination control and sterilization processes. Then, he became production manager before taking over the project management for the design and deployment of the new prosthesis manufacturing site. Finally, during his last 3 years, as Industrial Development Manager, he worked on the optimization of the manufacturing processes in order to increase the production rate.
Clément joined Flash Therapeutics in 2021 as Industrial Development and Production Manager in order to support the company in its industrial ramp-up to meet the growing demands of our customers.
Stéphane Carrasco - Industrial Development
After earning a master’s degree in Biochemical Engineering from the National Institute of Applied Sciences of Toulouse (INSA, France), Stéphane acquired bioprocess development expertise mainly in the Pharmaceutical Industry. He began his career in virological & bacteriological process development for animal vaccines at Merial Ltd., involved in various projects such as virus-inactivated, DNA plasmid or recombinant protein process development and alternative vaccine inactivation. Then, he joined Virbac laboratories for improvement of animal viral vaccine production processes and exploring innovative bioprocess & bioanalytical solutions, and moved to Merck Biodevelopment where he was involved in Quality By Design (QbD) studies for a phase II product. He joined Flash Therapeutics in a position of Industrial Development Manager so as to lead viral vectors process development & scaling-up team, with the objective of implementing the GMP lentiviral vector platform at Meary platform and on Flash Therapeutics own GMP facility at Toulouse, as well as to explore innovative bioproduction solutions for further manufacturing scaling-up.
Raphaël Sevrain – QC and Analytical Development
After an MSc degree in Virology, Vectorology and Gene Therapy from the University of Toulouse, France, Raphaël joined Vectalys in 2007 as an engineer of the Cell Models team in order to generate and characterize cellular models with lentiviral vectors. From 2012 to 2018 he was in charge of Cells Models project management from the scheduling of customer project to its delivery. Strong of his 11 years of experience in lentiviral vectors use, cell line engineering and characterization with a wide range of methods he is now in charge of Analytical Development since the end of 2018 in order to develop new methods and from end of 2021 he’s also in charge of Quality Control at FlashTherapeutics.
Régis Gayon - Project leader Cell Engineering and Vectorology
After an MSc degree in cellular and molecular biology from the University of Montpellier, France, Régis began his career in an academic laboratory (INSERM, Paris) where he initiated a transcriptomics project to help understand Type I diabetes. Régis then spent 5 years as an R&D associate scientist at Endocube (Toulouse, France) where he was involved in a cellular genomics project, acquiring expertise in the purification and culture of primary cells in the field of vascular biology. Régis joined Vectalys in 2005 as head of the Cell Models team. Since September 2012, he is also in charge of production development, purification and concentration of viral vectors, bringing his expertise in cellular biology to ensure performance and reliability of viral vectors produced at Vectalys. As head of the Vectors and Cell Models Teams, and strong of his experience of over 12 years in cellular and molecular biology, he oversees the viral vector production process and its enhancements, as well as manages the generation of new cellular models, from design to delivery, for use in the fields of bioproduction, gene target validation and drug discovery.
Christine Duthoit Ph.D - Project leader Cell Engineering and Immunology
Christine obtained her PhD in 2000 and then worked for eight years in the United States and France, where she successfully led various projects examining immune responses in different animal models for autoimmune diseases. She gained experience in in vivo experimentation, animal care, biochemistry and cell biology after spending several years in academic research before becoming the head of the Animal Models department at Vectalys in 2008. Her knowledge is now a key element for the development and testing of new animal models for Vectalys’ customers.
Sandy Darrigan - Contracts & Intellectual Property
After an initial qualification in cell biology and biotechnologies, Sandy specialized in intellectual property with a master’s degree of Intellectual Property and New technologies (Paul Sabatier University, Toulouse-France) and a master’s degree Patents and Trademarks of the Center for International Intellectual Property Studies (CEIPI, Strasbourg-France). After a first experience in a biotech company, Sandy joined Vectalys in 2012 to developp its patents portfolio. With these double skills, she is now in charge of Flash Therapeutics intellectual property strategy, including patents and in/out licences management. Her functions include the management of contractual aspects with Flash Therapeutics’ customers and partners.